PMID- 26307900
OWN - NLM
STAT- MEDLINE
DCOM- 20160729
LR  - 20221207
IS  - 1530-891X (Print)
IS  - 1530-891X (Linking)
VI  - 21
IP  - 12
DP  - 2015 Dec
TI  - SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF 
      T2DM.
PG  - 1315-22
LID - 10.4158/EP15877.OR [doi]
AB  - OBJECTIVE: To assess the real-world efficacy and safety of canagliflozin therapy 
      added to type 2 diabetes mellitus (T2DM) patients who have received a minimum 1 
      year of glucagon-like peptide-1 (GLP-1) agonist therapy. METHODS: This pre-post 
      observational study assessed the efficacy and safety of canagliflozin in a group 
      of T2DM patients from a community endocrinology practice who received GLP-1 
      agonist therapy for a minimum of 12 months. The primary study outcome was change 
      in mean glycated hemoglobin (HbA1c) level from baseline. Secondary endpoints 
      included changes in average weight, and comparison of the percentage of patients 
      obtaining an HbA1c <7%. RESULTS: A total of 75 patients met all the study 
      criteria. Baseline patient characteristics were as follows: average age, 58 +/- 9 
      years; mean duration of T2DM, 14 +/- 6 years; 56% male; 92% Caucasian; baseline 
      body mass index (BMI), 39.4 +/- 9.4 kg/m(2); and mean baseline HbA1c, 7.94 +/- 0.69%. 
      HbA1c and weight were significantly reduced by 0.39% and 4.6 kg, respectively. 
      Adverse effects were reported by 13 (17.3%) patients, including 4 (5.3%) who 
      discontinued canagliflozin because of adverse reactions. CONCLUSION: 
      Canagliflozin was generally well tolerated and significantly further reduced mean 
      HbA1c levels and body weight in patients with T2DM when added to GLP-1 regimen.
FAU - Saroka, Rachel M
AU  - Saroka RM
FAU - Kane, Michael P
AU  - Kane MP
FAU - Busch, Robert S
AU  - Busch RS
FAU - Watsky, Jay
AU  - Watsky J
FAU - Hamilton, Robert A
AU  - Hamilton RA
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20150826
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
CIN - Endocr Pract. 2015 Dec;21(12):1442-4. PMID: 26484408
MH  - Adult
MH  - Aged
MH  - Blood Glucose/drug effects
MH  - Body Weight/drug effects
MH  - Canagliflozin/*administration & dosage/adverse effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Glucagon-Like Peptide 1/administration & dosage/adverse effects/*agonists
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Treatment Outcome
EDAT- 2015/08/27 06:00
MHDA- 2016/07/30 06:00
CRDT- 2015/08/27 06:00
PHST- 2015/08/27 06:00 [entrez]
PHST- 2015/08/27 06:00 [pubmed]
PHST- 2016/07/30 06:00 [medline]
AID - S1530-891X(20)39370-8 [pii]
AID - 10.4158/EP15877.OR [doi]
PST - ppublish
SO  - Endocr Pract. 2015 Dec;21(12):1315-22. doi: 10.4158/EP15877.OR. Epub 2015 Aug 26.